Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
View original at finance.yahoo.comExelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types – Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif., May 21, 2026--(BUSINESS WIRE)--Exelixis, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The collective ASCO 2026 data sets demonstrate Exelixis's dedication to improving standards of care for patients with cancer
60% confidenceFindings from the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in metastatic colorectal cancer will be presented at ASCO 2026
60% confidenceNew analyses from the phase 3 CABINET pivotal trial further reinforce the foundational role of CABOMETYX in patient care
60% confidenceIn 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan
60% confidenceIn 2017, Exelixis granted Takeda Pharmaceutical Company Limited exclusive rights for cabozantinib commercialization and development for all future indications in Japan
60% confidenceCABOMETYX tablets have received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU
60% confidenceThe ASCO 2026 presentations highlight continued progress of Exelixis's strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib as the next oncology franchise molecule
60% confidenceExelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
60% confidence